Videos

Gifthealth's Chip Parkinson says direct-to-patient adoption has accelerated since January, driven by structural, not cyclical, market forces.

Gifthealth's Chip Parkinson revisits his 2026 outlook on the direct-to-patient model, and what's developed in H1.

Amy Niles of the Patient Advocate Foundation on the Medicare Part D cap, Medicaid, ACA exchanges and rural hospital access in late 2026.

Cencora's Brent Wilhelm on how specialty drug growth, cold chain demand, and reimbursement pressure are pushing distributors toward centralized safety stock and AI-driven flexibility.

Amy Niles of the Patient Advocate Foundation on Medicaid work requirements, ACA subsidy expiration and patient affordability in 2026.

Amy Niles of the Patient Advocate Foundation revisits her 2026 outlook on prior authorization reform and the Medicare Prescription Payment Plan.

Cencora's Brent Wilhelm explains why final-mile drug delivery hinges on carrier network visibility, and how AI is helping route around weather-driven disruptions.

Episode 1 of Supply Chain Signal breaks down the FDA's PreCheck pilot, the US Section 301 probe into German drug pricing, and CMS's move to make Medicare drug price negotiation permanent.

Brent Wilhelm of Cencora discusses why available inventory still leads to shortages, and how tighter distributor-manufacturer integration and AI could close the gap.

Deanna Horner, EVP of Enterprise DIRECT Strategy at EVERSANA, explains which therapeutic areas will lead DTP adoption and her five-year outlook for the model.

Deanna Horner, EVP of Enterprise DIRECT Strategy at EVERSANA, explains how real-time data generated through direct-to-patient models are shaping pharma's commercial decisions.

Deanna Horner, EVP of Enterprise DIRECT Strategy at EVERSANA, breaks down what's fueling pharma's embrace of direct-to-patient models.

Gerren McHam of the API Innovation Center on what a resilient US pharmaceutical supply chain looks like in five to ten years, and what execution actually requires.

Gerren McHam of the API Innovation Center outlines what a whole-of-government approach to meaningful pharmaceutical supply chain independence from China actually requires.

China's 2026 supply chain rules mean routine US trade compliance can now trigger Chinese export restrictions.

Cate Lockhart shares how manufacturers should communicate across mixed RWE data sources and what guardrails AI needs before payers can trust it.

Cate Lockhart explains why pharma-generated RWE quality isn't the issue, and how AMCP Standards are closing the communication gap with payers.

AMCP's Cate Lockhart on why only 18% of payers regularly use real-world evidence, and what the new AMCP RWE Standards are doing to change that.

PwC's Philip Sclafani discusses oral GLP-1 cost exposure, oncology drug spend under the medical benefit, and his outlook on PBM reform.

PwC’s Philip Sclafani discusses rising payer cost exposure, GLP-1 growth, and why pharmacy spending is outpacing medical cost trend heading into 2027.

Hear from Miranda Delatore, CoverMyMeds, on how a connected specialty access and affordability ecosystem is eliminating delays, reducing friction, and transforming the way biopharma manufacturers get patients started on life-changing therapies faster than ever before.

Danny Williams breaks down direct-to-patient distribution and his outlook on where pharma 3PLs are headed over the next five years.

Danny Williams discusses how AI has moved from experimental pilots to full operational deployment across supply chain functions, and how cell and gene therapies are reshaping the logistics industry.

EVERSANA's Danny Williams breaks down the most consequential operational shifts in pharma 3PL over the past five years, from full-pallet distribution to integrated commercialization support for complex, targeted therapies.

Learn how to navigate growing complexity, reduce workflow fragmentation, and design access and affordability programs that support patients throughout their treatment journey.

Will Shrank, MD, explains the main hurdles to specialty therapy access, and what will impact the market over the next few years.

Jessica Lovett explains the importance of being connected to the broader access ecosystem and how leveraging partnerships that can provide global insight and intelligence.

Tommy Bramley breaks down the benefits of incorporating real world evidence and data early into a product's lifecycle.